These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15271314)

  • 21. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal cell carcinoma in a von Hippel-Lindau syndrome: when should phaeochromocytoma be anticipated?
    Azarisman SM; Nor Azmi K
    Singapore Med J; 2007 Aug; 48(8):779-82. PubMed ID: 17657389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
    Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
    Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.
    Kobayashi A; Takahashi M; Imai H; Akiyama S; Sugiyama S; Komine K; Saijo K; Takahashi M; Takahashi S; Shirota H; Sato N; Fujishima F; Shuin T; Shimodaira H; Ishioka C
    Intern Med; 2016; 55(6):629-34. PubMed ID: 26984080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Von Hippel-Lindau disease: a case report.
    Dave B; Patel V; Murthy AK; Khasgiwala R
    Indian J Pathol Microbiol; 2003 Jul; 46(3):482-3. PubMed ID: 15025317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: treatment with interleukin-2.
    Williams C; Walther M
    ScientificWorldJournal; 2005 Jan; 5():9-10. PubMed ID: 15674444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
    Aiello LP; George DJ; Cahill MT; Wong JS; Cavallerano J; Hannah AL; Kaelin WG
    Ophthalmology; 2002 Sep; 109(9):1745-51. PubMed ID: 12208726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic renal cell carcinoma with metabolic syndrome--a case report.
    Kelly K; Cocklin C
    Clin Lab Sci; 2010; 23(3):141-5. PubMed ID: 20734886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
    O'Donnell A; Padhani A; Hayes C; Kakkar AJ; Leach M; Trigo JM; Scurr M; Raynaud F; Phillips S; Aherne W; Hardcastle A; Workman P; Hannah A; Judson I
    Br J Cancer; 2005 Oct; 93(8):876-83. PubMed ID: 16222321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.
    Girmens JF; Erginay A; Massin P; Scigalla P; Gaudric A; Richard S
    Am J Ophthalmol; 2003 Jul; 136(1):194-6. PubMed ID: 12834696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease.
    Tsimafeyeu I; Demidov L
    J Cancer Res Ther; 2010; 6(4):575-7. PubMed ID: 21358107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Von Hippel-Lindau Disease-Associated Microcystic Adenoma of the Ethmoid Sinus Mimicking Metastatic Clear Cell Renal Cell Carcinoma.
    Tsukamoto S; Koyasu S; Sugimoto A; Matsunaga M; Nakamoto Y
    Clin Nucl Med; 2023 Feb; 48(2):194-196. PubMed ID: 36179325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT.
    García Garzon JR; Bassa P; Llinares E; Soler M; Moragas M; Riera E
    Clin Nucl Med; 2015 Nov; 40(11):910-1. PubMed ID: 26252325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An unusual case of Von Hipple Lindau (VHL) syndrome with bilateral multicentric renal cell carcinoma with synchronous solitary urinary bladder metastasis.
    Dogra P; Kumar A; Singh A
    Int Urol Nephrol; 2007; 39(1):11-4. PubMed ID: 17268895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect?
    Taussky D; Soulières D
    Can J Urol; 2009 Apr; 16(2):4599-600. PubMed ID: 19364436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma.
    Bhatt RS; Zurita AJ; O'Neill A; Norden-Zfoni A; Zhang L; Wu HK; Wen PY; George D; Sukhatme VP; Atkins MB; Heymach JV
    Br J Cancer; 2011 Jun; 105(1):112-7. PubMed ID: 21673679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal cell carcinoma in von Hippel-Lindau disease: another piece of the puzzle.
    Chun SS; Green JS; Best L
    Can J Urol; 1994 Jan; 1(1):15-8. PubMed ID: 12834561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway].
    Kuefer R; Autenrieth M; Herkommer K; Blum P; Merseburger A; Hofer M; Rinnab L; Gschwend J; Ringhoffer M
    Urologe A; 2006 Mar; 45(3):328, 330-5. PubMed ID: 16465522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy.
    Richard S; Croisille L; Yvart J; Casadeval N; Eschwège P; Aghakhani N; David P; Gaudric A; Scigalla P; Hermine O
    Blood; 2002 May; 99(10):3851-3. PubMed ID: 11986247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting angiogenesis in metastatic renal cell carcinoma.
    Canino C; Perrone L; Bosco E; Saltalamacchia G; Mosca A; Rizzo M; Porta C
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):245-257. PubMed ID: 30678509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.